{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T01:05:29Z","timestamp":1768784729468,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.amjmed.2016.01.039","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T21:07:07Z","timestamp":1455916027000},"page":"661-666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016"],"prefix":"10.1016","volume":"129","author":[{"given":"Murray","family":"Epstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Duprez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2016.01.039_bib1","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"51","author":"Calhoun","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2016.01.039_bib2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/ajh\/hpu151","article-title":"Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations","volume":"28","author":"Achelrod","year":"2015","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.amjmed.2016.01.039_bib3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11906-007-0018-2","article-title":"The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy","volume":"9","author":"Epstein","year":"2007","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.amjmed.2016.01.039_bib4","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7326\/0003-4819-150-11-200906020-00005","article-title":"Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension","volume":"150","author":"Sowers","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1 Suppl 1","key":"10.1016\/j.amjmed.2016.01.039_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1524-6175.2007.06367.x","article-title":"Aldosterone and the vasculature: mechanisms mediating resistant hypertension","volume":"9","author":"Duprez","year":"2007","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.amjmed.2016.01.039_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-042711-135929","article-title":"Hyperaldosteronism as a common cause of resistant hypertension","volume":"64","author":"Calhoun","year":"2013","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.amjmed.2016.01.039_bib7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jash.2014.06.005","article-title":"Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013","volume":"8","author":"White","year":"2014","journal-title":"J\u00a0Am Soc Hypertens"},{"key":"10.1016\/j.amjmed.2016.01.039_bib8","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/CIRCULATIONAHA.111.030189","article-title":"Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008","volume":"124","author":"Egan","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2016.01.039_bib9","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1097\/00004872-200111000-00018","article-title":"High prevalence of cardiac and extra- cardiac target organ damage in refractory hypertension","volume":"19","author":"Cuspidi","year":"2001","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.amjmed.2016.01.039_bib10","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.amjhyper.2005.05.014","article-title":"Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension","volume":"18","author":"Pierdomenico","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.amjmed.2016.01.039_bib11","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2016.01.039_bib12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/HYPERTENSIONAHA.114.04012","article-title":"Trends in blood pressure among adults with hypertension: United States, 2003 to 2012","volume":"65","author":"Yoon","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2016.01.039_bib13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/archinte.162.4.413","article-title":"Physician-related barriers to the effective management of uncontrolled hypertension","volume":"162","author":"Oliveria","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2016.01.039_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11906-015-0579-4","article-title":"Can drugs work in patients who do not take them? The problem of non-adherence in resistant hypertension","volume":"17","author":"Ruzicka","year":"2015","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.amjmed.2016.01.039_bib15","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/HJH.0b013e32835e2286","article-title":"Resistant hypertension? Assessment of adherence by toxicological urine analysis","volume":"31","author":"Jung","year":"2013","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.amjmed.2016.01.039_bib16","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/heartjnl-2013-305063","article-title":"High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LCMS\/MS) urine analysis","volume":"100","author":"Tomaszewski","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.amjmed.2016.01.039_bib17","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A\u00a0randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2016.01.039_bib18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.HYP.0000150859.47929.8e","article-title":"Recommendations for blood pressure measurement in humans and animals. Part 1: Blood pressure measurement in humans","volume":"45","author":"Pickering","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2016.01.039_bib19","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/0002-9343(86)90636-4","article-title":"Osler's maneuver, pseudohypertension, and true hypertension in the elderly","volume":"80","author":"Messerli","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2016.01.039_bib20","unstructured":"Noncommunicable diseases: a major health challenge of the 21st century. In: World Heath Statistics 2012, ed. World Health Organization:34-37. Available at: www.who.int\/gho\/publications\/world_health_statistics\/2012\/en\/. Accessed January 27,\u00a02016."},{"key":"10.1016\/j.amjmed.2016.01.039_bib21","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1097\/00004872-200112000-00022","article-title":"High prevalence of unrecognized sleep apnoea in drug-resistant hypertension","volume":"19","author":"Logan","year":"2001","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.amjmed.2016.01.039_bib22","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/jhh.2015.15","article-title":"Obstructive sleep apnea, hypertension and cardiovascular diseases","volume":"29","author":"Gonzaga","year":"2015","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.amjmed.2016.01.039_bib23","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1378\/chest.06-1442","article-title":"Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension","volume":"131","author":"Pratt-Ubunama","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2016.01.039_bib24","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jash.2008.05.005","article-title":"Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension","volume":"2","author":"Calhoun","year":"2008","journal-title":"J\u00a0Am Soc Hypertens"},{"key":"10.1016\/j.amjmed.2016.01.039_bib25","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/ajh\/hpv031","article-title":"The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies","volume":"28","author":"Dahal","year":"2015","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.amjmed.2016.01.039_bib26","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/S0140-6736(15)00264-0","article-title":"Spironolactone for resistant hypertension\u2013hard to resist?","volume":"386","author":"Sternlicht","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2016.01.039_bib27","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/jhh.2009.96","article-title":"Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report","volume":"24","author":"Gaddam","year":"2010","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.amjmed.2016.01.039_bib28","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","article-title":"Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial","volume":"57","author":"V\u00e1clav\u00edk","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2016.01.039_bib29","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","article-title":"Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial","volume":"31","author":"Oxlund","year":"2013","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.amjmed.2016.01.039_bib30","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2016.01.039_bib31","article-title":"Safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies","author":"Lentini","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"issue":"Suppl 3","key":"10.1016\/j.amjmed.2016.01.039_bib32","first-page":"A14271","article-title":"Patiromer controls hyperkalemia in resistant hypertensive patients on RAASi, with diabetic kidney disease","volume":"132","author":"Epstein","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2016.01.039_bib33","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(09)61500-2","article-title":"A\u00a0selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Weber","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2016.01.039_bib34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/15701611113119990137","article-title":"The future of interventional management of hypertension: threats and opportunities","volume":"12","author":"Briasoulis","year":"2014","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.amjmed.2016.01.039_bib35","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrcardio.2015.96","article-title":"Carotid baroreflex activation therapy for resistant hypertension","volume":"12","author":"Victor","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.amjmed.2016.01.039_bib36","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jacc.2011.06.008","article-title":"Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos Pivotal Trial","volume":"58","author":"Bisognano","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2016.01.039_bib37","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jash.2012.01.003","article-title":"Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial","volume":"6","author":"Bakris","year":"2012","journal-title":"J\u00a0Am Soc Hypertens"},{"key":"10.1016\/j.amjmed.2016.01.039_bib38","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(09)60566-3","article-title":"Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study","volume":"373","author":"Krum","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2016.01.039_bib39","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A\u00a0controlled trial of renal denervation for resistant hypertension","volume":"370","author":"Bhatt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2016.01.039_bib40","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jash.2014.12.002","article-title":"Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the \u201cend of the road\u201d for renal denervation?","volume":"9","author":"Epstein","year":"2015","journal-title":"J\u00a0Am Soc Hypertens"},{"key":"10.1016\/j.amjmed.2016.01.039_bib41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/HYPERTENSIONAHA.115.06526","article-title":"Role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized PRAGUE-15 study","volume":"67","author":"Rosa","year":"2016","journal-title":"Hypertension"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934316301735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934316301735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:09:17Z","timestamp":1757581757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934316301735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0002934316301735"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2016.01.039","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2016.01.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}